TY  - JOUR
AU  - Andrejević, Tina P.
AU  - Nikolić, Andrea M.
AU  - Glisić, Biljana D.
AU  - Wadepohl, Hubert
AU  - Vojnović, Sandra
AU  - Zlatović, Mario
AU  - Petković, Miloš
AU  - Nikodinović-Runić, Jasmina
AU  - Opsenica, Igor M.
AU  - Đuran, Miloš, I
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3086
AB  - Herein, we report the synthesis and structural characteristics of three tetrazole-containing compounds, 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-tetrazol-5-amine (bntza) and 1-(4-methoxybenzyl)-1H-tetrazol-5-amine (mbntza) and the corresponding silver(I) complexes of the general formula [Ag(NO3-O)(L-N4)(2)](n), L = bntz (1), bntza (2) and mbntza (3). Silver(I) complexes 1-3 and 1-benzyl-1H-tetrazoles have been studied in detail by NMR, IR and UV-Vis spectroscopic methods and the structures of 1 and 2 have been determined by single-crystal X-ray diffraction analysis. The results of these analyses revealed a monodentate coordination of the ligands to Ag(I) ion via the N4 tetrazole nitrogen. The antimicrobial potential of silver(I) complexes 1-3 was evaluated against the broad panel of Gram-positive and Gram-negative bacteria and fungi, displaying their remarkable inhibiting activity with MIC (minimal inhibitory concentration) values in the range 2-8 and 0.16-1.25 mu g/mL (3.8-16.3 and 0.31-2.15 mu M), respectively. On the other hand, 1-benzyl-1H-tetrazoles used for the synthesis of the silver(I) complexes were not active against the investigated strains, suggesting that the activity of the complexes originates from the Ag(I) ion exclusively. Moreover, silver(I) complexes 1-3 have good therapeutic potential, which can be deduced from their moderate cytotoxicity on the human fibroblast cell line MRC5, with IC50 values falling in the range 30-60 mu g/mL (57.7-103.4 mu M).
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Polyhedron
T1  - Synthesis, structural characterization and antimicrobial activity of silver(I) complexes with 1-benzyl-1H-tetrazoles
VL  - 154
SP  - 325
EP  - 333
DO  - 10.1016/j.poly.2018.08.001
ER  - 

@article{
author = "Andrejević, Tina P. and Nikolić, Andrea M. and Glisić, Biljana D. and Wadepohl, Hubert and Vojnović, Sandra and Zlatović, Mario and Petković, Miloš and Nikodinović-Runić, Jasmina and Opsenica, Igor M. and Đuran, Miloš, I",
year = "2018",
abstract = "Herein, we report the synthesis and structural characteristics of three tetrazole-containing compounds, 1-benzyl-1H-tetrazole (bntz), 1-benzyl-1H-tetrazol-5-amine (bntza) and 1-(4-methoxybenzyl)-1H-tetrazol-5-amine (mbntza) and the corresponding silver(I) complexes of the general formula [Ag(NO3-O)(L-N4)(2)](n), L = bntz (1), bntza (2) and mbntza (3). Silver(I) complexes 1-3 and 1-benzyl-1H-tetrazoles have been studied in detail by NMR, IR and UV-Vis spectroscopic methods and the structures of 1 and 2 have been determined by single-crystal X-ray diffraction analysis. The results of these analyses revealed a monodentate coordination of the ligands to Ag(I) ion via the N4 tetrazole nitrogen. The antimicrobial potential of silver(I) complexes 1-3 was evaluated against the broad panel of Gram-positive and Gram-negative bacteria and fungi, displaying their remarkable inhibiting activity with MIC (minimal inhibitory concentration) values in the range 2-8 and 0.16-1.25 mu g/mL (3.8-16.3 and 0.31-2.15 mu M), respectively. On the other hand, 1-benzyl-1H-tetrazoles used for the synthesis of the silver(I) complexes were not active against the investigated strains, suggesting that the activity of the complexes originates from the Ag(I) ion exclusively. Moreover, silver(I) complexes 1-3 have good therapeutic potential, which can be deduced from their moderate cytotoxicity on the human fibroblast cell line MRC5, with IC50 values falling in the range 30-60 mu g/mL (57.7-103.4 mu M).",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Polyhedron",
title = "Synthesis, structural characterization and antimicrobial activity of silver(I) complexes with 1-benzyl-1H-tetrazoles",
volume = "154",
pages = "325-333",
doi = "10.1016/j.poly.2018.08.001"
}

Andrejević, T. P., Nikolić, A. M., Glisić, B. D., Wadepohl, H., Vojnović, S., Zlatović, M., Petković, M., Nikodinović-Runić, J., Opsenica, I. M.,& Đuran, M. I.. (2018). Synthesis, structural characterization and antimicrobial activity of silver(I) complexes with 1-benzyl-1H-tetrazoles. in Polyhedron
Pergamon-Elsevier Science Ltd, Oxford., 154, 325-333.
https://doi.org/10.1016/j.poly.2018.08.001

Andrejević TP, Nikolić AM, Glisić BD, Wadepohl H, Vojnović S, Zlatović M, Petković M, Nikodinović-Runić J, Opsenica IM, Đuran MI. Synthesis, structural characterization and antimicrobial activity of silver(I) complexes with 1-benzyl-1H-tetrazoles. in Polyhedron. 2018;154:325-333.
doi:10.1016/j.poly.2018.08.001 .

Andrejević, Tina P., Nikolić, Andrea M., Glisić, Biljana D., Wadepohl, Hubert, Vojnović, Sandra, Zlatović, Mario, Petković, Miloš, Nikodinović-Runić, Jasmina, Opsenica, Igor M., Đuran, Miloš, I, "Synthesis, structural characterization and antimicrobial activity of silver(I) complexes with 1-benzyl-1H-tetrazoles" in Polyhedron, 154 (2018):325-333,
https://doi.org/10.1016/j.poly.2018.08.001 . .

TY  - JOUR
AU  - Pejcić, Tomislav P.
AU  - Tulić, Cane
AU  - Lalić, Nataša V.
AU  - Glisić, Biljana D.
AU  - Ignjatović, Svetlana
AU  - Marković, Biljana
AU  - Hadzi-Đokić, Jovan B.
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1978
AB  - PEJCIC TP, TULIC CD, LALIC NV, GLISIC BD, IGNJATOVIC SD, MARKOVIC BB, HADZI-DJOKK JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression? Can J Urol 2013;20(2):6707-6713. Introduction: Urinary prostate-specific antigen (uPSA) can be used as additional parameter of benign prostatic hyperplasia (BPH) progression. Materials and methods: From January 2001 to December 2011, uPSA was determined in 265 patients with benign prostate. Based on total prostate volume (TPV), the patients with benign prostate were divided in two groups: TPV  lt 31 mL and TPV >= 31 mL. Additional three groups were formed upon MTOPS study criteria: non-progressive BPH group (TPV  lt  31 mL, PSA  lt  1.6 ng/mL, age  lt  62 yrs), intermediate group (one, or two parameters {TPV, PSA, age} increased) and progressive BPH group (TPV >= 31 ml, PSA >= 1.6 ng/mL, age >= 62 yrs). Results: Average uPSA values in the groups TPV  lt 31 mL and TPV 31 mL were 119.3 +/- 124.5 and 255.5 +/- 204.9 ng/mL, respectively and they were significantly different (p  lt  0.0001). Average uPSA values in the non-progressive BPH group, intermediate group and progressive BPH group were 86.8 +/- 82.4 ng/mL, 166.6 +/- 164.9 ng/mL and 274.9 +/- 208.3 ng/mL, respectively and they were significantly different (p  lt  0.0001). The level of uPSA correlated significantly with TPV (r = 0.32, p  lt  0.0001). The cut off uPSA level of 150 ng/mL discriminates the patients with non-progressive BPH and progressive BPH with specificity of 0.83 and sensitivity of 0.67. Conclusion: The level of uPSA reflects prostatic hormonal activity and correlates with TPV, PSA and age. UPSA level >= 150 ng/mL can be used as additional predictive parameter of BPH progression.
PB  - Canadian J Urology, St Laurent
T2  - Canadian Journal of Urology
T1  - Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
VL  - 20
IS  - 2
SP  - 6707
EP  - 6713
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1978
ER  - 

@article{
author = "Pejcić, Tomislav P. and Tulić, Cane and Lalić, Nataša V. and Glisić, Biljana D. and Ignjatović, Svetlana and Marković, Biljana and Hadzi-Đokić, Jovan B.",
year = "2013",
abstract = "PEJCIC TP, TULIC CD, LALIC NV, GLISIC BD, IGNJATOVIC SD, MARKOVIC BB, HADZI-DJOKK JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression? Can J Urol 2013;20(2):6707-6713. Introduction: Urinary prostate-specific antigen (uPSA) can be used as additional parameter of benign prostatic hyperplasia (BPH) progression. Materials and methods: From January 2001 to December 2011, uPSA was determined in 265 patients with benign prostate. Based on total prostate volume (TPV), the patients with benign prostate were divided in two groups: TPV  lt 31 mL and TPV >= 31 mL. Additional three groups were formed upon MTOPS study criteria: non-progressive BPH group (TPV  lt  31 mL, PSA  lt  1.6 ng/mL, age  lt  62 yrs), intermediate group (one, or two parameters {TPV, PSA, age} increased) and progressive BPH group (TPV >= 31 ml, PSA >= 1.6 ng/mL, age >= 62 yrs). Results: Average uPSA values in the groups TPV  lt 31 mL and TPV 31 mL were 119.3 +/- 124.5 and 255.5 +/- 204.9 ng/mL, respectively and they were significantly different (p  lt  0.0001). Average uPSA values in the non-progressive BPH group, intermediate group and progressive BPH group were 86.8 +/- 82.4 ng/mL, 166.6 +/- 164.9 ng/mL and 274.9 +/- 208.3 ng/mL, respectively and they were significantly different (p  lt  0.0001). The level of uPSA correlated significantly with TPV (r = 0.32, p  lt  0.0001). The cut off uPSA level of 150 ng/mL discriminates the patients with non-progressive BPH and progressive BPH with specificity of 0.83 and sensitivity of 0.67. Conclusion: The level of uPSA reflects prostatic hormonal activity and correlates with TPV, PSA and age. UPSA level >= 150 ng/mL can be used as additional predictive parameter of BPH progression.",
publisher = "Canadian J Urology, St Laurent",
journal = "Canadian Journal of Urology",
title = "Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?",
volume = "20",
number = "2",
pages = "6707-6713",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1978"
}

Pejcić, T. P., Tulić, C., Lalić, N. V., Glisić, B. D., Ignjatović, S., Marković, B.,& Hadzi-Đokić, J. B.. (2013). Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?. in Canadian Journal of Urology
Canadian J Urology, St Laurent., 20(2), 6707-6713.
https://hdl.handle.net/21.15107/rcub_farfar_1978

Pejcić TP, Tulić C, Lalić NV, Glisić BD, Ignjatović S, Marković B, Hadzi-Đokić JB. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?. in Canadian Journal of Urology. 2013;20(2):6707-6713.
https://hdl.handle.net/21.15107/rcub_farfar_1978 .

Pejcić, Tomislav P., Tulić, Cane, Lalić, Nataša V., Glisić, Biljana D., Ignjatović, Svetlana, Marković, Biljana, Hadzi-Đokić, Jovan B., "Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?" in Canadian Journal of Urology, 20, no. 2 (2013):6707-6713,
https://hdl.handle.net/21.15107/rcub_farfar_1978 .